We had the honor of welcoming 3 experts:
Professor Aurélien Marabelle is a clinician and researcher with expertise in oncology (MD) and immunology (PhD). His clinical practice is dedicated to early phase clinical trials of cancer immunotherapies. He works as principal investigator of clinical trials within the Drug Development Department (DITEP) of Gustave Roussy and coordinates a translational research team on tumor immunology attached to INSERM and the University of Paris-Saclay. It will show how to improve the success rate of early phase clinical trials in oncology.
Nolwen Guigal-Stephan, PhD, Global Head of Clinical Biomarker Development at Servier, is responsible for leading the team to develop the biomarker strategy and its implementation to facilitate evidence-based decision making. biomarkers in clinical trials in oncology and other pathologies. She will present circulating tumor DNA as a key biomarker for decision-making in early clinical drug development.
Sofia Ioannidou holds a PhD in Cellular Biology from Cancer Research UK. She joined the Andera Partners investment fund team in 2009 and was promoted to Associate Director in 2019. She will discuss an investor's perspective on biomarkers in oncology and their use by biotechnology companies.
watch the replay:
コメント